Dr. John Chant

“Nothing would make me more satisfied than to know we have given others a longer, healthier life with happiness.”

Dr. Chant joined Filtricine as CEO in December 2020. As a successful entrepreneur, he saw incredible potential in Filtricine and Tality. He decided to lead this revolutionary nutrition-based approach to cancer care. Previously, Dr. Chant served as founder/CEO of two successful oncology startups: G1 Therapeutics (NASDAQ: GTHX) and Gatekeeper Pharmaceuticals.  In 2018 he spun out AlphaEleven Therapeutics from the University of California San Francisco to commercialize inhibitors of clotting factor XI as next generation anticoagulants. He's held research and development positions with CuraGen and Genentech. Dr. Chant holds a PhD from the University of California San Francisco and served on the faculty of Harvard University early in his career.